Company news

Scynexis, Inc. news in 2026

Scynexis, Inc.'s news releases, calls and decks from 2026, newest first.

View company

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 5, 2026

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

October 29, 2026

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

October 22, 2026

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

October 21, 2026

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

October 6, 2026

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

September 28, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

September 22, 2026

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

September 15, 2026

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10, 2026

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

March 30, 2026

SCYNEXIS Announces $40.0 Million Private Placement

March 30, 2026

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

March 3, 2026

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

February 25, 2026

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

February 17, 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

January 28, 2026

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

January 21, 2026

Decks in 2026